Gilead Sciences (GILD) emerges as the better investment compared to Amgen (AMGN) due to its lower price point and more favorable beta, suggesting a slightly lower risk profile. While both companies lack specific P/E and EPS metrics, GILD's beta of 0.374 indicates less volatility relative to the market, making it more appealing for risk-averse investors. The growth trajectory of GILD, particularly in the antiviral market, positions it favorably for future revenue expansion, enhancing its overall investment attractiveness.

Gilead Sciences should appeal to investors seeking growth with lower risk, while Amgen may be best suited for those favoring established drug manufacturers. Prioritizing GILD can capitalize on its growth potential in a less volatile environment.